Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase.

Sci Transl Med 2017 04;9(387)

Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized mouse model, and modest reductions in mouse-to-mouse transmission were achieved in the mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a monkey model. Both genomic and chemoproteomic studies identified a kinase of the parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aad9735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731459PMC
April 2017
61 Reads

Publication Analysis

Top Keywords

mouse model
8
phosphatidylinositol 4-kinase
8
ability mmv390048
8
cycle stages
8
life cycle
8
mmv390048
6
transmission achieved
4
experiments monkeys
4
achieved mouse
4
model experiments
4
monkeys revealed
4
mmv390048 full
4
mmv390048 eliminate
4
eliminate liver
4
chemoprotection mmv390048
4
full chemoprotection
4
mouse-to-mouse transmission
4
revealed ability
4
model modest
4
stages apart
4

References

(Supplied by CrossRef)
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
Schleiferböck et al.
Drug Des. Devel. Ther. 2013

Similar Publications